华森制药
(002907)
| 流通市值：40.34亿 | | | 总市值：54.54亿 |
| 流通股本：3.09亿 | | | 总股本：4.18亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 691,542,793.48 | 515,257,554.58 | 360,455,416.63 | 187,539,020.46 |
| 营业收入 | 691,542,793.48 | 515,257,554.58 | 360,455,416.63 | 187,539,020.46 |
| 二、营业总成本 | 655,558,798.19 | 467,711,274.31 | 317,792,881.58 | 151,822,163.07 |
| 营业成本 | 311,348,443.65 | 222,654,037.36 | 154,448,892.28 | 74,438,227.92 |
| 税金及附加 | 11,008,221.34 | 7,104,821.87 | 5,441,599.58 | 1,781,182.49 |
| 销售费用 | 210,739,675.26 | 157,757,827.64 | 109,708,337.6 | 52,929,378.1 |
| 管理费用 | 53,139,702.38 | 37,168,323.73 | 24,454,577.72 | 11,650,036.97 |
| 研发费用 | 78,119,916.11 | 49,402,354.9 | 28,914,218.36 | 14,151,767.59 |
| 财务费用 | -8,797,160.55 | -6,376,091.19 | -5,174,743.96 | -3,128,430 |
| 其中:利息费用 | 945,351.05 | 916,908.42 | 637,784.38 | 169,531.9 |
| 其中:利息收入 | 9,810,172.49 | 7,338,713.8 | 5,842,236.6 | 3,312,105.69 |
| 加:公允价值变动收益 | 3,452,053.36 | - | - | - |
| 加:投资收益 | -8,121,359.49 | -5,339,465.57 | -3,076,796.81 | -1,730,411.53 |
| 资产处置收益 | 58,474.68 | 58,474.68 | 58,474.68 | 58,474.68 |
| 资产减值损失(新) | -1,097,450.45 | -868,259.43 | -383,192.97 | -276,738.27 |
| 信用减值损失(新) | 1,594,783.82 | 1,645,786.78 | 1,642,495.38 | 377,771.13 |
| 其他收益 | 13,952,536.22 | 8,652,056.35 | 6,240,449.04 | 1,600,680.24 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 45,823,033.43 | 51,694,873.08 | 47,143,964.37 | 35,746,633.64 |
| 加:营业外收入 | 148,645.15 | 132,429.44 | 66,721.13 | 34,324.24 |
| 减:营业外支出 | 3,174,905.81 | 311,530.48 | 10,037.78 | 5,037.78 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 42,796,772.77 | 51,515,772.04 | 47,200,647.72 | 35,775,920.1 |
| 减:所得税费用 | 10,097,622.55 | 6,740,765.27 | 5,838,527.98 | 5,675,378.21 |
| 六、净利润 | 32,699,150.22 | 44,775,006.77 | 41,362,119.74 | 30,100,541.89 |
| 持续经营净利润 | 32,699,150.22 | 44,775,006.77 | 41,362,119.74 | 30,100,541.89 |
| 归属于母公司股东的净利润 | 32,699,150.22 | 44,775,006.77 | 41,362,119.74 | 30,100,541.89 |
| (一)基本每股收益 | 0.08 | 0.11 | 0.1 | 0.07 |
| (二)稀释每股收益 | 0.08 | 0.11 | 0.1 | 0.07 |
| 八、其他综合收益 | 47,047.57 | 651,711.7 | 762,330.62 | -55,429.94 |
| 归属于母公司股东的其他综合收益 | 47,047.57 | 651,711.7 | 762,330.62 | -55,429.94 |
| 九、综合收益总额 | 32,746,197.79 | 45,426,718.47 | 42,124,450.36 | 30,045,111.95 |
| 归属于母公司股东的综合收益总额 | 32,746,197.79 | 45,426,718.47 | 42,124,450.36 | 30,045,111.95 |
| 公告日期 | 2024-04-10 | 2023-10-27 | 2023-08-22 | 2023-04-28 |
| 审计意见(境内) | 标准无保留意见 | | | |